14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
WVE vs MLTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, MoonLake Immunotherapeutics Class A (MLTX) captures the overall head-to-head institutional edge over Wave Life Sciences Ltd. (WVE) on higher Unified Composite conviction (38.3/100 SELL vs. 41.5/100 SELL) after splitting the core matrix 4–4 (led by Profitability & Quality, Options & Positioning), while WVE wins 3–2 across the 6-pillar growth and valuation breakdown. WVE trades at $2.89 (N/M Forward P/E, -320.9% operating margin) versus MLTX at $11.85 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While WVE currently prints a higher short-term Unified Composite Score (41.5/100 SELL vs. MLTX 38.3/100 SELL), MLTX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -320.9% operating margin) and revenue trajectory (+0.0% vs. +73.0% YoY).
Defensive Composite Rating Caution: Although MLTX compares more favorably head-to-head, both WVE (41.5/100 SELL) and MLTX (38.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: WVE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.1); meanwhile MLTX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on WVE vs MLTX. Trailing 12-month operating profitability (WVE -320.9% vs MLTX 0.0%) and valuation multiples (WVE N/M vs MLTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ WVE vs MLTX Key Questions & Quantitative Answers
As of Nov 16, 2026, MoonLake Immunotherapeutics Class A (MLTX) captures the overall head-to-head institutional edge over Wave Life Sciences Ltd. (WVE) on higher Unified Composite conviction (38.3/100 SELL vs. 41.5/100 SELL) after splitting the core matrix 4–4 (led by Profitability & Quality, Options & Positioning), while WVE wins 3–2 across the 6-pillar growth and valuation breakdown. WVE trades at $2.89 (N/M Forward P/E, -320.9% operating margin) versus MLTX at $11.85 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While WVE currently prints a higher short-term Unified Composite Score (41.5/100 SELL vs. MLTX 38.3/100 SELL), MLTX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -320.9% operating margin) and revenue trajectory (+0.0% vs. +73.0% YoY). Defensive Composite Rating Caution: Although MLTX compares more favorably head-to-head, both WVE (41.5/100 SELL) and MLTX (38.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: WVE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.1); meanwhile MLTX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
WVE leads the Growth & Scale pillar: WVE posts +73.0% YoY revenue growth and +0.0% YoY earnings growth on $71M TTM revenue (N/A gross margin, -320.9% operating margin), compared with MLTX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, WVE generates $71M in USD-normalized revenue versus N/A for MLTX. In operating R&D and SG&A reinvestment, WVE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MLTX.
WVE screens cheaper on headline valuation multiples. WVE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin), whereas MLTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against WVE (-78.8% ROE) versus MLTX (-81.5% ROE) capital efficiency.
In options market volatility and institutional positioning, WVE carries 605.7% implied volatility (62nd %ile, Elevated (60th–80th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.94β · 76% Vol realized risk). By comparison, MLTX carries 111.8% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.61β · 90% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.